Visionary Thinking Group

Transcription

1 Visionary Thinking Group Ideate. Implement. Iterate. Market-Altering Solutions 12/31/2017 1

2 About Visionary Thinking Group (VTG) VTG is a Client-Value-Multiplier. We have developed solutions for clients that - change market dynamics - address key unmet needs in large markets - result in big revenue and profit gains for our clients - give our clients a clear Competitive Advantage VTG develops these solutions for clients who can commercialize them - OEMs - Contract Manufacturers - Investor Groups - Research Facilities VTG earns a share of the revenue from the products we create 12/31/2017 2

3 Examples of Our Solutions VTG s solutions are revolutionary, not evolutionary Client and Product Pre-VTG Post-VTG Infrared Densitometer Monitor $125 Cost High Failure Rate Was PC-sized High cost $10 cost 99.9% reliability Many added automated features Is Palm-sized Operational costs reduced by 80% Range of function increased by 90% High failure rate Has 99.9% reliability Diesel Injector Solenoid Zero added cost 12/31/2017 3

4 Worldwide Wearables Market - Sales Revenue Global Wearables market is forecasted to grow to over $40 Billion by 2021 VTG has 5 solutions for this market $42.7 $30.7 Sales US $ Billions $15.4 * Includes activity trackers, heart rate monitors, pedometers and home monitoring ** Includes wearable cameras, smart glasses, healthcare devices, wearable 3D motion trackers, smart clothing and wearables 12/31/2017 Source: Worldwide Consumer Technology Association, ABI Research,

5 VTG Research Technology Portfolio VTG has in research 9 proprietary solutions demonstrating initial positive results. $4.7 Billion ROYALTY revenue potential to VTG per 2 independent valuations* Target Market VTG Proprietary Solutions Medical 1. Glucose Fusion Non-invasive monitoring and insulin dispensing Medical 2. TouchSole Sensory feedback network for people with neuropathy Medical 3. Non-Invasive Dialysis A better method for kidney dialysis Medical 4. BioSensor Array Implantable sensors to monitor body metrics Medical 5. Holistic Body Scanner Non-invasive capture of vitals / organ status Food Service 6. BeValve Automated sensory + control for perfect drink dispensing Automotive + Industrial 7. TorqueShaft Driveshaft with integrated motor and drive assembly Automotive + Industrial 8. Smart Sensors Tiny sensors to monitor industrial & automotive devices Energy & Utilities 9. Intuitive Meters Real-time smart meters for electricity, gas and water * VTG Portfolio assessed by two independent valuation firms; Pro Rata royalty VALUE is in addition to manufacturers COGS + Profit Margin Note: Several products listed here are under Provisional Patent Protection; IP filing efforts underway for the others 12/31/2017 5

6 Self-Monitoring Glucose Device Market VTG s Glucose Fusion product targets an $11 Billion market (2015) Growing at a 5.7% CAGR through 2022 $20 B $15 B $10 B $5 B 12/31/ Source: P&S Market Research, September 2015

7 VTG Fusion Value Proposition Integrated No-Needles or Test Strips - Glucometer/Insulin dispensing System; (global market for Glucometer only by 2020= US$12.1Bn; per Global Industry Analysts, Inc.) Glucose Monitoring & Dispensing Today Invasive must draw blood and use needle to inject insulin. Costly must repeatedly buy needles and test-strips. VTG Fusion - A new and better approach to Glucose Monitoring & Insulin Dispensing Non-Invasive. Measures glucose without need to draw blood - Glucose population measured via proprietary dermal penetration with near IR spectroscopy. - Preliminary results available - Calibrated with Abbott Freestyle Lite Glucose Meter No consumables! Needle-free and test-strip free Need 2 Devices for Monitoring Glucose & Dispensing Insulin. Monitor glucose & dispense insulin from one proprietary device. High accuracy pump delivers insulin can handle 2 types. - Uses piezoelectric for dermal penetration no needle. - Sensor integrated within syringe for calibrated dosage. - Chamber sensors ensure accurate delivery. 12/31/2017 7

8 Fusion Laboratory Testing Data Fusion reliability is on par with two industry gold standards devices Achieved non-invasively! Bench-top model Testing 2 x per day for 30 days 12/31/2017 8

9 Fusion Multi-Function Glucose Device Delivery Chamber Internal Subassembly Carbonate Shield Housing Multi-type Insulin Dispenser Silicone Se Ready Color Indicator Test Result Display Patent Pending 12/31/2017 9

10 Neuropathy Market Peripheral Neuropathy (PN) is a disorder of the peripheral nervous system The nerves connecting the spinal cord to muscles, skin and internal organs are damaged Usually affects the feet and hands, causing weakness, numbness, tingling and pain. Problem: It inhibits the ability to feel pain or changes in temperature in feet / hands So people cannot sense if they have been injured from a cut / stepped on a sharp object Or that a wound on the foot is becoming infected - a big problem for many diabetics 20 million Americans suffer from PN including: 60-70% of people with Diabetes Many people with auto-immune diseases (Sjogrens, Lupus, Rheumatoid Arthritis, HIV) People with Kidney Disorders ~40% of Cancer survivors who underwent Chemotherapy 12/31/

11 VTG TouchSole - Sensory Feedback for Neuropathy TouchSole Neuropathic feedback socks; (A recent study from Persistence Market Research predicts the global compression therapy industry will expand at a compounded annual growth rate of 5.2 percent between 2014 and The study concluded that the industry, which was valued at $2.38 billion in 2014, will balloon to $3.23 billion in This is without factoring our sensory feedback capability). TouchSole is a Patented sensory feedback device for lower extremities built into compression socks Provides artificial sensation via an assembled network of tri-axial sensors for injury detection (impact) and future injury prevention The readings from cushioned triaxial accelerometers in the sole are routed to transducers integrated at the calf of the socks to provide electrical stimulation Each sensor reads directional change in three dimensions, sending an electrical sensation to the wearer s calf as to movement /directional change of the foot. The triaxial accelerometers are MEMS-created strain-gage devices - used for decades by the auto industry for crash sensors which deploy airbags. 12/31/

12 Hemodialysis Dialysis Market Today End Stage Renal Dialysis (ESRD) is a large and growing market 660,000 people in the U.S., 2 million globally Growing by 5-7% annually Nearly 6,500 Dialysis facilities in the U.S. ESRD treatment is also very costly 7% of the total Medicare budget, even though ESRD = only 1% of Medicare patients $34 Billion = Total annual Medicare cost to treat kidney failure $89K = Average annual cost for treatment per patient in the U.S. Current treatment method is time-consuming, confining and debilitating Patient tethered to machine at a dialysis facility, 3x per week, 3-5 hours per session Invasive process draw blood to analyze and treat it, remove toxins Exhausting for patients little/no energy after each session High morbidity rate. Only 35% survival rate after 5 years of treatment Source: U.S. Renal Data System Annual Data Report (2015), Centers for Medicare & Medicaid Services 12/31/

13 VTG s Laboratory Dermodialysis Testing Dermodialysis, No-Stick Hemodialysis/Peritoneal Dialysis; (The market is expected to reach US $83.89 Billion by 2021, growing at a CAGR of 6.0% from 2016 to 2021; per Markets and Markets, Inc.) Non-Invasive procedure no need to draw and recirculate blood - achieved by Hyperhidrosis, not blood Chemical makeup determined by captured fluids - using an array of appropriately-scaled liquid micro-chromatographs. - requisite organic replacement determined by attending nephrologist Administration of organic replacement is done orally, not by injection Device size and treatment duration vary by individual - Optimization requires further research. 12/31/

14 Summary VTG is seeking a vested strategic partner to help capitalize & drive the commercialization of the ever-growing list of solutions in our portfolio. Strategic partner participation: funding, technical collaboration and marketing. We value a long-term synergistic partnership. Our strategic partner shares Pro Rata in projected US$7.09Bn of Royalties with a projected ROI ramping to >40% < 5five years. VTG will secure the first best partnership in the shortest time practical. 12/31/

15 Contact Steven Sable Chairman Raffi Sahul, Ph.D. EVP/Strategic Corporate Development /31/